IOB - Delayed Quote EUR

Grifols, S.A. (0RDV.IL)

6.66

-0.03

(-0.37%)

At close: January 29 at 2:35:29 PM GMT

Gotham, Grifols Eye Two Separate Regulator Reports Ahead of Legal Standoff

(Bloomberg) -- Drugmaker Grifols SA and US short seller Gotham City Research are counting on two different reports from a Spanish regulator to bolster their cases as they prepare to face off in court.Most Read from BloombergTexas HOA Charged With Discrimination for Banning Section 8 RentersHow Sanctuary Cities Are Preparing for Another Showdown With TrumpDonations to LA Fire Victims Rise Past $200 Million MarkNY’s Hochul Calls for Law Banning Cell Phone Use in SchoolsLA Schools Wrecked by Fires

Bloomberg 9 days ago

GRFS
Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson’s Disease

‘Chronos-PD’ is looking for biological signals that could indicate increased chance of developing Parkinson’s disease (PD) years before symptoms appear, leading to new diagnostic tools and disease-modifying therapiesPart of broad Grifols program to find disease-revealing clues in more than 100 million proprietary plasma samples connected to real-world data on thousands of disease states in many therapeutic areasCutting-edge use of AI and proteomics technology paired with real-world evidence unde

GlobeNewswire 17 days ago

GIFLF

GIFOF

GIKLY
Mason Capital complains about Grifols' transparency to Spanish regulator

U.S.-based investment fund Mason Capital said on Monday it had sent a letter to Spain's stock market regulator CNMV demanding more transparency from the embattled pharmaceutical company Grifols. The activist fund said in a statement it had identified potential conflicts of interest linked to related party transactions by current board members, failure of internal controls and a "rumoured clause" in a recent bond issuance that benefits Canadian fund Brookfield at shareholders' expense. "We urge the CNMV to consider the benefits to all Grifols shareholders from improved disclosure," Mason Capital said.

Reuters 18 days ago

GRFS
Exploring Three High Growth Tech Stocks For Future Potential

As global markets navigate a mixed economic landscape marked by declining consumer confidence and fluctuating indices, technology stocks continue to capture attention with their potential for high growth. In this environment, identifying promising tech stocks involves assessing factors such as innovation, market demand, and the ability to adapt to changing economic conditions.

Simply Wall St. 30 days ago

GIFLF

GIFOF

GIKLY
Exploring High Growth Tech Stocks This December 2024

As global markets reach new heights, with indices like the Russell 2000 hitting record intraday highs, investor sentiment remains buoyed by domestic policy developments and easing geopolitical tensions. In this environment, identifying high-growth tech stocks that can capitalize on current economic trends and technological advancements is crucial for investors seeking to navigate the evolving landscape of December 2024.

Simply Wall St. last month

GIFLF

GIFOF

GIKLY
Sector Update: Health Care Stocks Slipping Late Afternoon

Health care stocks were easing late Monday afternoon, with the NYSE Health Care Index and the Health

PREMIUM
MT Newswires last month

PTCT

SNTI

NVS
Why Is Spanish Healthcare Grifols Stock Trading Lower On Friday?

On Wednesday, Grifols SA (NASDAQ:GRFS) said it ended discussions with Brookfield Capital Partners (UK) Limited about a potential acquisition. This decision follows the company’s November 19 statement rejecting Brookfield’s indicative offer to acquire Grifols for 6.45 billion euros ($6.81 billion) or 10.50 euros per Class A share. Canadian fund Brookfield said it had dropped its plan to take over Spain’s Grifols due to a disagreement over the pharmaceutical company’s value, while Grifols said it

Benzinga 2 months ago

GRFS
Grifols Stock Declines After Brookfield Drops Buyout Offer

Brookfield decides to drop its buyout offer for GRFS following discrepancies over the company's valuation.

Zacks 2 months ago

GRFS

BAM

SPRO
Sector Update: Health Care Stocks Rise in Late Afternoon Trading

Health care stocks were higher late Wednesday afternoon, with the NYSE Health Care Index and the Hea

PREMIUM
MT Newswires 2 months ago

GRFS

BAM
Top Midday Decliners

Symbotic (SYM) said it submitted a notification of late filing for its annual report for the fiscal

PREMIUM
MT Newswires 2 months ago

GRFS

SYM
Update: Market Chatter: Grifols' Family Won't Welcome Other Takeover Bids as Brookfield Walks Away

(Updates with Brookfield statement in the second paragraph.) Grifols (GRFS) has decided not to we

PREMIUM
MT Newswires 2 months ago

GRFS

BAM
Sector Update: Health Care Stocks Rise Pre-Bell Wednesday

Health care stocks rose premarket Wednesday as the Health Care Select Sector SPDR Fund (XLV) advance

PREMIUM
MT Newswires 2 months ago

GRFS

OTLK
Market Chatter: Brookfield Set to Drop Grifols Bid as Family Shuns Others

Brookfield Asset Management Ltd. is preparing to walk away from a plan to acquire Grifols SA over di

PREMIUM
MT Newswires 2 months ago

GRFS

BAM
Market Chatter: Grifols' Family Won't Welcome Other Takeover Bids as Brookfield Walks Away

Grifols (GRFS) has decided not to welcome a new takeover bid by a third-party as Brookfield Asset Ma

PREMIUM
MT Newswires 2 months ago

GRFS

BAM
Grifols shares tumble after Brookfield drops takeover plan

MADRID (Reuters) -Canadian fund Brookfield said on Wednesday it has dropped its plan to take over Spain's Grifols due to a disagreement over the pharmaceutical company's value, while Grifols said it concurred with the decision. Brookfield had filed a non-binding offer on Nov. 19 for Grifols that valued the developer of human plasma-based drugs at 6.45 billion euros ($6.79 billion), which Grifols then said was a significantly undervalued offer and told its shareholders to stick to their shares. Grifols shares closed 9.07% down on Wednesday after falling more than 12% in earlier trading after Bloomberg first reported Brookfield's decision.

Reuters 2 months ago

GRFS
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%

Per GRFS, Brookfield's offer to buy its entire outstanding share capital for 6.45 billion euros significantly undervalues GRFS' prospects and long-term potential.

Zacks 2 months ago

GRFS

BAM

CTMX
GigaGen commences Phase I clinical trial of GIGA-2339 for hepatitis B treatment

The potency of GIGA-2339 is claimed to be more than 2,000 times greater than that of plasma-derived HBV treatments.

Clinical Trials Arena 2 months ago

GRFS
Grifols: Brookfield's potential $6.8 billion offer undervalues the firm

MADRID (Reuters) -Grifols said on Tuesday that Canadian investment fund Brookfield's potential 6.45 billion euro ($6.8 billion) offer significantly undervalued the Spanish drugmaker's prospects and long-term potential, telling shareholders to stick to their shares. Earlier on Tuesday, Brookfield said it was considering a public offer for Grifols at 10.50 euros per A share and 7.62 euros per B share, implying a company valuation of 6.45 billion euros. The proposal is non-binding, Brookfield said in a filing to the Spanish stock market regulator.

Reuters 2 months ago

GRFS
GigaGen Doses First Patient in Phase 1 Trial of Recombinant Polyclonal Drug Candidate, GIGA-2339, for Hepatitis B Virus

GIGA-2339 contains more than 1,000 fully human recombinant anti-HBV antibodies and is the first recombinant polyclonal therapeutic in development to treat and functionally cure chronic HBV infectionSAN CARLOS, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immunodeficiencies, infectious diseases and checkpoint-resistant cancers, and a subsidiary of Grifols, announced today that the first patient has been dosed in a Phas

GlobeNewswire 2 months ago

GIFLF

GIFOF

GIKLY
Market Chatter: Canada's Brookfield Reportedly Plans to Offer About 7-billion Euros For Spanish drugmaker Grifols

Market Chatter: Canada's Brookfield Reportedly Plans to Offer About 7-billion Euros For Spanish drugmaker Grifols

PREMIUM
MT Newswires 2 months ago

GRFS

Performance Overview

Return	0RDV.IL	IBEX 35...
YTD	-4.99%	+7.21%
1-Year	-12.79%	+23.20%
3-Year	-34.48%	+43.66%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Grifols, S.A. (0RDV.IL)

Gotham, Grifols Eye Two Separate Regulator Reports Ahead of Legal Standoff

Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson’s Disease

Mason Capital complains about Grifols' transparency to Spanish regulator

Exploring Three High Growth Tech Stocks For Future Potential

Exploring High Growth Tech Stocks This December 2024

Sector Update: Health Care Stocks Slipping Late Afternoon

Why Is Spanish Healthcare Grifols Stock Trading Lower On Friday?

Grifols Stock Declines After Brookfield Drops Buyout Offer

Sector Update: Health Care Stocks Rise in Late Afternoon Trading

Top Midday Decliners

Update: Market Chatter: Grifols' Family Won't Welcome Other Takeover Bids as Brookfield Walks Away

Sector Update: Health Care Stocks Rise Pre-Bell Wednesday

Market Chatter: Brookfield Set to Drop Grifols Bid as Family Shuns Others

Market Chatter: Grifols' Family Won't Welcome Other Takeover Bids as Brookfield Walks Away

Grifols shares tumble after Brookfield drops takeover plan

Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%

GigaGen commences Phase I clinical trial of GIGA-2339 for hepatitis B treatment

Grifols: Brookfield's potential $6.8 billion offer undervalues the firm

GigaGen Doses First Patient in Phase 1 Trial of Recombinant Polyclonal Drug Candidate, GIGA-2339, for Hepatitis B Virus

Market Chatter: Canada's Brookfield Reportedly Plans to Offer About 7-billion Euros For Spanish drugmaker Grifols

Performance Overview